Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sanofi (SNYNF – Research Report), Incyte (INCY – Research Report) and Ventyx Biosciences (VTYX – Research Report).
Sanofi (SNYNF)
J.P. Morgan analyst Richard Vosser maintained a Hold rating on Sanofi today and set a price target of EUR98.00. The company’s shares closed last Thursday at $99.25.
According to TipRanks.com, Vosser is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sanofi with a $113.51 average price target, implying an 11.9% upside from current levels. In a report issued on April 25, DZ BANK AG also maintained a Hold rating on the stock.
See today’s best-performing stocks on TipRanks >>
Incyte (INCY)
In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Hold rating on Incyte, with a price target of $62.00. The company’s shares closed last Thursday at $53.50.
According to TipRanks.com, Ahmad is a 2-star analyst with an average return of
Currently, the analyst consensus on Incyte is a Moderate Buy with an average price target of $70.07, which is a 30.3% upside from current levels. In a report issued on April 30, RBC Capital also maintained a Hold rating on the stock with a $60.00 price target.
Ventyx Biosciences (VTYX)
In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Ventyx Biosciences. The company’s shares closed last Thursday at $4.48, close to its 52-week low of $1.87.
According to TipRanks.com, Slutsky is a 5-star analyst with an average return of
Ventyx Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $11.71, implying a 160.2% upside from current levels. In a report released yesterday, Wells Fargo also maintained a Buy rating on the stock with a $16.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SNYNF:
- Pfizer agrees to settle over 10,000 Zantac cancer suits, Bloomberg reports
- Denali Therapeutics reports Q1 EPS (68c), consensus (70c)
- FTC expands patent listing challenges for drugs
- Sanofi price target raised to EUR 98 from EUR 94 at JPMorgan
- Sanofi expects FY24 business EPS to remain relatively stable
